1-800-710-4674

Find a Doctor

Return to Physician Search

Physician Profile

 

Patrick John Ward, M.D., PhD

“I believe patients should be offered leading edge care and given every opportunity to participate in their care decisions with the guidance and support from their medical team.”
Learn More.

Practices

Hematology
Medical Oncology

Locations

Blue Ash

Request
appointment

or call
1-800-710-4674

SPECIALTIES

Breast cancer
Clinical research

MEDICAL INTERESTS

Clinical research

PERSONAL INTERESTS

Spending time with family, traveling, and pursuing an interest in microbrewery beer.

MEDICAL SCHOOL

The Ohio State University

INTERNSHIP

The Ohio State University

RESIDENCY

The Ohio State University

FELLOWSHIP

The Ohio State University, James Cancer Hospital

CERTIFICATIONS & LICENSURES

American Board of Internal Medicine, Internal Medicine
American Board of Internal Medicine, Medical Oncology

MEMBERSHIPS

American Association for the Advancement of Science
American Chemical Society
American College of Physicians

COMMITTEES

Vice Chairman, Oncology Section, Department of Internal Medicine, Bethesda North Hospital

Ward P.J.; Hsiao, A.; Song, X.; Chen, C.; Cyclooxygenase-2 independent induction of breast tumor cell death by novel celecoxib analogs. 93rd Annual Meeting of the American Association for Cancer Research, San Francisco, California; 2002

Brueggemeier, RW; O’Reilly, JM; Lovely, CJ; Ward, PJ; Quinn, AL; Baker, D; Darby, MV; Gu, XJ; Gilbert, NE Biochemistry and pharmacology of 7-alpha-substituted androstenediones as aromatase inhibitors. J Steroid Biochem Mol Biol 1997, 61(3-6), 247-54

Ward P.J.; Lovely, C.J.; Sharp, D.W.; Quinn, A.L.; Brueggemeier, R.W. Mammary Tumor Growth Inhibition and Endocrine Effects of Aromatase Inhibitor 7a-APTADD in a Rat Model.  Midwest Regional Symposium on Medicinal Chemistry; Pittsburgh, PA; 1995

Ward, P.J.; Lovely, C.J.; Sharp, D.W.; Quinn, A.L.; Brueggemeier, R.W. Growth Suppression of DMBA-Induced Mammary Tumors in Rats by Aromatase Inhibitor 7-a-Aminophenylthio-1,4-androstadiene-3,20-dione.  IX International Congress on Hormonal Steroids; Dallas, TX; 1994

As a member of our OHC physician team, Dr. Ward has full access to the OHC Clinical Trial research program.

We encourage our patients to discuss all of their healthcare options — including Clinical Trial research programs — with their doctor.

The following are recent reviews provided by actual OHC patients:

"My doctor is Patrick Ward. He always spends time talking to me about what is happening in the research community involving breast cancer. I realize that I may have to wait a while, but I feel he gives me his undivided attention and he must do the same for others. It is nice not to have a doctor sitting at a computer typing during my appointment!"

"My life has been saved by Dr. Ward!"

"My treatment has always been excellent and Dr. Ward always answers any questions I have. He is always well informed and provides good explanations. Thank you for offering a high level of care."